vilobelimab

DRUG3 trials

Sponsors

InflaRx GmbH

Conditions

Pyoderma GangrenosumSCC - Squamous Cell Carcinoma of Skin

Phase 2

Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

CompletedNCT03971643

InflaRx GmbHPyoderma Gangrenosum

Start: 2019-05-16End: 2022-01-03Updated: 2023-09-14

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

TerminatedNCT04812535

InflaRx GmbHSCC - Squamous Cell Carcinoma of Skin

Start: 2021-03-31End: 2024-06-04Updated: 2025-02-11

Phase 3

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

TerminatedNCT05964413

InflaRx GmbHPyoderma Gangrenosum

Start: 2023-11-01End: 2025-07-11Updated: 2025-11-04